UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)

Trial Profile

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Lenalidomide; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms TT4B
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
    • 09 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
    • 06 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top